Pfizer CEO Albert Bourla on Monday flagged issues with the leadership of the U. Food and Drug Administration's vaccine ...
One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp ...
Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.
Opinion
COVID vaccine liability lawsuit dismissed by rubber-stamp judicial panel that botched law: lawyer
Neither trial nor appeals court seems to understand the procedure for "willful misconduct" claims under the PREP Act, says lawyer for estate of college student who died from COVID vaccine.
The US Food and Drug Administration has issued emergency use authorization (EUA) for the Covid-19 vaccine developed by Pfizer and BioNTech. After months of development, emergency use was authorized ...
A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...
Drugmaker Pfizer said Friday that as government contracts come to an end, possibly by early next year, its COVID-19 vaccine will be sold for $110 to $130 per dose. This price model comes down to ...
PHILADELPHIA -- To help fend off another wave of Covid-19, people will need a fourth dose of vaccine, Pfizer CEO Albert Bourla said Sunday. "Many variants are coming, and Omicron was the first one ...
A lawmaker compared getting the vaccine with using meth. The Idaho Medical Association said his bill would infringe on ...
By Mariam Sunny March 2 (Reuters) - Pfizer CEO Albert Bourla said the company "has a problem" with the U.S. Food and Drug Administration's biologics and vaccines chief, Vinay Prasad, in response to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results